MorphoSys Foresees 10 New Program Starts In 2014, Earnings Deficit

MorphoSys expects both partnered and proprietary activities to generate around 10 new program starts this year as the German biotech strongly boosts its R&D investment, a plan that will generate its first earnings shortfall in a decade.